Hims & Hers Health, Inc. (HIMS)

NYSE · San Francisco, California, USA · Founded 2017 · CEO Andrew Dudum

Valuation summary

$21.36 fair value versus $16.02 in the market, a difference of +33.3%. Rated Strong Buy.

Fair value per share$21.36
Current share price$16.02
Upside / downside+33.3%
Bear case$11.75
Bull case$35.07
Discount rate (WACC)11.9%
Terminal growth2.80%
Market capitalisation$4B
EV / Sales1.6x

About Hims & Hers Health, Inc.

Founded in 2017 by Andrew Dudum, who is chief executive. Hims & Hers is an online health company: customers consult a clinician through its app and receive treatments by post on subscription, for hair loss, sexual health, skin, mental health and weight loss. Selling its own lower-priced versions of popular weight-loss injections drove very fast growth and also brought disputes with drug makers and regulators. It has expanded into Europe by buying the online clinic Zava.

Investment case

  • More than two million subscribers and a strong consumer brand.
  • Personalised treatments are harder for pharmacies to copy.
  • Profitable, with new categories such as hormone health and lab testing.

Key risks

  • Its weight-loss business depends on rules about compounded drugs that keep changing.
  • Large marketing spending is needed to keep adding customers.
  • Drug makers now sell directly to patients at lower prices.

Revenue by segment

Online subscriptions97%
Wholesale3%

Five-year forecast

RevenueFree cash flow
Year 1$3.7B$0.2B
Year 2$4.6B$0.3B
Year 3$5.5B$0.4B
Year 4$6.3B$0.5B
Year 5$6.9B$0.6B

What the street says

A divisive stock: fans see a consumer health platform, critics a business built on a regulatory gap.

Comparable companies: HUM · TEM · ALNY · MDLN · NTRA · DXCM · GEHC · BSX

Open the interactive model, price chart and sensitivity grid →